The global thrombophilia treatment market is estimated to garner a large amount of revenue by growing at a significant CAGR over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the growing burden of obesity, and increasing prevalence of cardiovascular and trauma cases across the world. According to the World Health Organization, as of now, cardiovascular diseases account for about 17.9 million deaths, which is an estimated 32 percent of all the deaths globally.
Along with these, rise in consumption of alcohol and tobacco is predicted to add a risk of development of high blood pressure on veins leading to several thrombophilia complications, which in turn is expected to fuel the market growth in the upcoming years. Furthermore, escalating research and development spending in the field of hematological diseases, and government initiatives to raise awareness regarding blood disorders are projected to offer profitable opportunities to the market in the near future.
The market is segmented by end user into hospitals, homecare, specialty centers, and others, out of which, the hospitals segment is anticipated to hold the largest share in the global thrombophilia treatment market. This can be accounted to the high preference of patients to get their treatment by a healthcare professional operating in a hospital facility, and increase in the number of hospital admissions. Additionally, on the basis of type, the factor V Leiden segment is evaluated to acquire the largest share during the forecast period, which can be credited to the commonness of this type of thrombophilia among the general population. Apart from this, the upsurge in the number of people with genetic mutations around the globe is also assessed to drive growth to the market segment in the imminent time. CLICK TO DOWNLOAD SAMPLE REPORT
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
On the basis of geographical analysis, the global thrombophilia treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market in the Asia Pacific is estimated to witness noteworthy growth over the forecast period on the back of the growing investments for improving healthcare infrastructure, and larger patient pool in the region. Moreover, the market in North America is expected to occupy the largest share during the forecast period ascribing to the rising demand for progressive treatment options, and early adoption of technologies, especially in the United States. In addition, increasing geriatric population, and growing collaboration of domestic and international companies for awareness campaigns are also predicted to boost the region’s market growth in the coming years. As per the data given by Rural Health Information Hub, there are more than 46 million adults aged 65 years or older living in the United States as of 2019. By 2050, this number is anticipated to reach almost 90 million.
The global thrombophilia treatment market is further classified on the basis of region as follows:
Our in-depth analysis of the global thrombophilia treatment market includes the following segments:
FREQUENTLY ASKED QUESTIONS
The major factors driving market growth are growing burden of obesity, and increasing prevalence of cardiovascular and trauma cases worldwide.
The market is anticipated to attain a significant CAGR over the forecast period, i.e., 2022 – 2030.
Poor reimbursement policies provided by government is estimated to hamper the market growth.
Asia Pacific will provide more business opportunities for market growth owing to the growing investments for improving healthcare infrastructure, and larger patient pool in the region.
The major players in the market are Sanofi SA, Pfizer, Inc., Aspen Pharmacare Holdings Limited, Boehringer Ingelheim GmbH, and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by type, drugs, end user, and by region.
The hospitals segment is anticipated to hold largest market size and is estimated to grow at a notable CAGR over the forecast period and display significant growth opportunities.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization